Dr. Campelo on the Rationale for the ALTA-1L Trial

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK positive non-small cell lung cancer patients who were treated with brigatinib versus crizotinib.

NSCLC,non–small cell lung cancer,lung cancer,brigatinib,crizotinib,Rosario Garcia Campelo MD,Onclive,WCLC19,